MMR-vaccine

Phase 3Vaccine

GSK

MMR-vaccine is one of 12 biologic programs targeting Chickenpox. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxRecruiting

ChickenpoxPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Chickenpox

#DrugCompanyPhaseTrials

Zovirax

BBp Consulting, Inc

Approved

—2

Investigational Cancer Drug

GSK

Phase 3

5 3

Marketed Paracetamol

GSK

Phase 3

5 4

Hepatitis a Vaccine

Sanofi

Phase 3

5 5

Vaxneuvance

GSK

Phase 3

4 6

PCV 20

GSK

Phase 3

4 7

Candidate Varicella Vaccine

GSK

Phase 3

1 8

MMR-vaccine

GSK

Phase 3

3 9

YF-Vax

Sanofi

Preclinical

1 10

Valtrex

GGlaxo Dba Glaxosmithkline

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Chickenpox

NCT06855160

Q2 2027

Phase 3Recruiting

Chickenpox

NCT06806137

Phase 3Recruiting

Chickenpox

NCT06740630

Q2 2031

Post-ApprovalNot yet recruiting

Study completion

NCT06920069

Clinical

Trials by Indication[1]

Immunogenicity4 trials

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Completed· Sanofi logo

Sanofi·Phase 3·NCT03547271·1,660 enrolled

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01553279·284 enrolled

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations

Completed·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT01777529·240 enrolled

Show 1 more trial

Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children

Completed·SSerum Institute of India Pvt. Ltd.·Phase 4·NCT02253407·341 enrolled

Chickenpox3 trials

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06740630·1,840 enrolled

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06855160·900 enrolled

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06806137·600 enrolled

COVID-191 trial

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Completed·LLouisiana State University Health Sciences Center in New Orleans·Phase 3·NCT04475081·50 enrolled

Immunity1 trial

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Completed·—··NCT00962819·74 enrolled

Vaccines1 trial

Live Vaccines and Innate Immune Training in COPD.

Completed·JJosefin Eklöf·Phase 4·NCT06257212·60 enrolled

3 more indications

Genital Warts1 trial

Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts

Unknown status·—·Phase 3·NCT03853785·45 enrolled

Chikungunya1 trial

Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

Completed·TThemis Bioscience GmbH·Phase 2·NCT03101111·34 enrolled

Unspecified2 trials

Zambia SiVET MMR Tdap-IPV

Completed·EEmory University·Phase 1/2·NCT02589678·160 enrolled

Study of Concomitant Administration of the sIPV and DTaP or MMR

Not yet recruiting·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 4·NCT06920069·2,640 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for MMR-vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MMR-vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MMR-vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: GSK

MMR-vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2031

Trials by Indication[1]

Immunogenicity4 trials

Chickenpox3 trials

COVID-191 trial

Immunity1 trial

Vaccines1 trial

Genital Warts1 trial

Chikungunya1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News